Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (21-30 of 129) with videos related to

Pageof 13
Sort By:
Blood|October 7, 2006
Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many yearsRosemary E Gale, Anthony J R Allen, Michael J Nash, et al.
British Journal of Haematology|February 18, 2003
Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapyPhil J Ancliff, Rosemary E Gale, Ri Liesner, et al.
Leukemia Research|June 14, 2003
Incidence and prognostic significance of C-MPL expression in acute myeloid leukemiaSivatharsini Chelvatheebam, Stephen E Langabeer, David C Linch, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
Hodgkin's Lymphoma: Choice of Therapy and Late ComplicationsDavid C. Linch, Roger G. Gosden, Togas Tulandi, et al.
British Journal of Haematology|December 6, 2021
Therapy for isocitrate dehydrogenase 2 (IDH2)<sup>R172</sup> -mutant acute myeloid leukaemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
British Journal of Haematology|October 10, 2019
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
BMJ (Clinical Research Ed.)|March 12, 2010
Treatment for lymph node tuberculosisRob S Sellar, E L Corbett, Shirley D'Sa, et al.
Praxis|August 26, 2010
[Therapy of lymph node tuberculosis]Rob S Sellar, E L Corbett, Shirley D'Sa, et al.
Blood|May 24, 2014
Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
British Journal of Haematology|August 11, 2016
Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: Implications for quality assuranceMichael J Watts, Stuart J Ings, Carmen Balsa, et al.
Pageof 13

Showing results (21-30 of 129) with videos related to

Sort By:
Pageof 13
Blood|October 7, 2006
Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many yearsRosemary E Gale, Anthony J R Allen, Michael J Nash, et al.
British Journal of Haematology|February 18, 2003
Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapyPhil J Ancliff, Rosemary E Gale, Ri Liesner, et al.
Leukemia Research|June 14, 2003
Incidence and prognostic significance of C-MPL expression in acute myeloid leukemiaSivatharsini Chelvatheebam, Stephen E Langabeer, David C Linch, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
Hodgkin's Lymphoma: Choice of Therapy and Late ComplicationsDavid C. Linch, Roger G. Gosden, Togas Tulandi, et al.
British Journal of Haematology|December 6, 2021
Therapy for isocitrate dehydrogenase 2 (IDH2)<sup>R172</sup> -mutant acute myeloid leukaemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
British Journal of Haematology|October 10, 2019
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
BMJ (Clinical Research Ed.)|March 12, 2010
Treatment for lymph node tuberculosisRob S Sellar, E L Corbett, Shirley D'Sa, et al.
Praxis|August 26, 2010
[Therapy of lymph node tuberculosis]Rob S Sellar, E L Corbett, Shirley D'Sa, et al.
Blood|May 24, 2014
Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
British Journal of Haematology|August 11, 2016
Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: Implications for quality assuranceMichael J Watts, Stuart J Ings, Carmen Balsa, et al.
Pageof 13